Other · developed by MBX Biosciences
MBX 4291 is an agent administered subcutaneously.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07142707 | Phase 1 | Obesity | Recruiting | MBX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Obesity
Updated Oct 18, 2026. Something wrong or missing? Report it on the MBX page.
See MBX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MBX catalysts and pipeline →